CKD is classified by a two-dimensional grid of GFR and albuminuria stages that together define prognosis and guide therapy. Under the KDIGO guidelines, kidney damage or reduced function must persist for at least 3 months. The system combines five glomerular filtration rate categories (G1–G5) with three albuminuria categories (A1–A3) to produce a risk matrix. For anyone building diagnostic staging assays, accurately measuring serum creatinine, urinary albumin, and cystatin C is the non‑negotiable foundation that powers this classification.
The KDIGO framework turns CKD from a single‑number label into a risk map. Assays that deliver precise, standardized results for serum creatinine, urinary albumin, and cystatin C are what make that map legible—enabling early detection, accurate staging, and targeted intervention.
How CKD is Classified: The KDIGO Two‑Dimensional Staging
The current KDIGO classification (Kidney Disease: Improving Global Outcomes) is built on two independent dimensions. Each provides complementary information; neither alone is sufficient for full risk assessment.
The GFR Grid: G1 to G5
GFR is the anchor for staging kidney function.
- G1: ≥90 mL/min/1.73 m² – normal or high function, but with other signs of kidney damage.
- G2: 60–89 mL/min/1.73 m² – mildly decreased function.
- G3a: 45–59 mL/min/1.73 m² – mild to moderate decrease.
- G3b: 30–44 mL/min/1.73 m² – moderate to severe decrease.
- G4: 15–29 mL/min/1.73 m² – severe decrease.
- G5: <15 mL/min/1.73 m² – kidney failure.
A patient is only classified as having CKD if the reduced GFR is accompanied by markers of kidney damage, or if the GFR is already below 60 mL/min/1.73 m².
Albuminuria Categories: A1 to A3
Persistent albuminuria is the most sensitive marker of kidney damage in many diseases.
- A1: Urine albumin‑to‑creatinine ratio (ACR) <30 mg/g (<3 mg/mmol). Normal to mildly increased.
- A2: ACR 30–300 mg/g (3–30 mg/mmol). Moderately increased (formerly “microalbuminuria”).
- A3: ACR >300 mg/g (>30 mg/mmol). Severely increased (clinical albuminuria).
The ACR must be abnormal on at least two out of three measurements over 3 months to rule out transient spikes.
The Combined Risk Matrix
When G‑stage and A‑stage are plotted on a grid, each cell carries a different prognosis for kidney failure, cardiovascular events, and mortality. For example, a person with G2 A1 is at much lower risk than someone with G3b A2. This two‑axis model drives every modern clinical decision—from medication choice to nephrology referral thresholds.
Key Biomarkers for Diagnostic Staging Assays
Building a panel that maps directly to the KDIGO grid demands robust, quantitative measurement of three core analytes.
Serum Creatinine: The Workhorse of GFR Estimation
Serum creatinine is the starting point for most estimated GFR (eGFR) equations. It is a breakdown product of muscle metabolism, produced at a relatively constant rate.
- Why it matters: eGFR formulas like CKD‑EPI use serum creatinine, age, sex, and race‑neutral factors to assign a G‑stage.
- Assay implications: Accuracy is paramount. Small biases in the creatinine measurement can shift a patient from G2 to G3a—altering their entire risk profile and treatment plan.
Urinary Albumin: The Marker of Kidney Damage
Urinary albumin (measured as ACR in a spot urine sample) directly defines the A‑stage and is the earliest sign of glomerular injury.
- Why it matters: Even modest increases (A2) signal a significantly elevated cardiovascular risk and are a trigger for renoprotective therapies.
- Assay implications: Assays must detect very low albumin concentrations with high precision. Sensitivity at the 3 mg/mmol cutoff is non‑negotiable, and results must be standardized to creatinine to correct for urine concentration.
Cystatin C: Refining Risk in the G3 “Gray Zone”
Cystatin C is a low‑molecular‑weight protein produced by all nucleated cells and filtered freely by the glomerulus. It is less influenced by muscle mass than creatinine.
- Why it matters: In patients with GFR between 45 and 59 mL/min/1.73 m² (G3a), creatinine‑based eGFR can misclassify risk. The KDIGO guidelines recommend measuring cystatin C when confirmation is needed.
- Assay implications: A dual‑marker approach (creatinine + cystatin C) produces a more reliable eGFR and can reclassify patients out of the indeterminate CKD zone. This directly impacts the design of reflex testing algorithms in staging kits.
Understanding the Limitations and Pitfalls in Assay Development
Even the best‑defined biomarkers carry technical hurdles that can undermine staging accuracy. Anticipating these pitfalls is essential for building a reliable diagnostic product.
Creatinine Standardization Is Not Optional
Jaffe vs. enzymatic methods: Traditional alkaline picrate (Jaffe) methods suffer from interferences (glucose, proteins, cephalosporins). Enzymatic assays offer better specificity but require traceability to IDMS‑standardized reference materials. Without rigorous calibration, eGFR results become non‑transferable between laboratories.
Albuminuria Measurement Is Biologically Variable
Urine albumin excretion fluctuates with exercise, posture, fever, and hydration. A single spot ACR can be misleading. Diagnostic panels must therefore encourage or embed repeat‑testing logic, and the assay itself must be highly reproducible across a wide dynamic range.
Cystatin C Still Lacks Universal Harmonization
Despite progress, cystatin C assays do not yet have the global standardization that creatinine does. Manufacturers must invest in certified reference materials and cross‑platform comparability to ensure that cystatin C‑based eGFR equations yield consistent results across instruments and regions.
Over‑Reliance on a Single Marker
A panel that only reports creatinine‑based eGFR will miss many patients in the moderate‑risk G3a/A2 range. Conversely, measuring albumin alone without a reliable GFR surrogate fails to stage the functional loss. The full grid requires both. Assay developers must think in combinations, not isolated tests.
Making the Right Choice for Your Renal Panel
Your target application decides which marker depth and testing algorithm you need.
- If your primary focus is population screening: Build an affordable, high‑throughput panel around serum creatinine and a sensitive ACR. The goal is to catch the silent majority with early damage.
- If your primary focus is precise, guideline‑compliant staging: Include cystatin C as a reflex or confirmatory marker, especially for patients who fall into the G3a category. This enhances risk reclassification and aligns with KDIGO recommendations.
- If your primary focus is monitoring progression in established CKD: Prioritize long‑term precision and lot‑to‑lot consistency for both creatinine and albumin. Small drifts can be misinterpreted as disease worsening.
Ultimately, the KDIGO grid is more than a classification—it’s a clinical action map. When your assays faithfully measure the biomarkers that define each axis, you give clinicians the power to intervene before kidney function is irretrievably lost.
Summary Table:
| Biomarker | KDIGO Dimension | Clinical Role | Key Development Consideration |
|---|---|---|---|
| Serum Creatinine | GFR Staging (G1–G5) | Primary anchor for eGFR estimation | Requires IDMS standardization; enzymatic methods preferred over Jaffe |
| Urinary Albumin (ACR) | Albuminuria Staging (A1–A3) | Early indicator of glomerular damage & CV risk | Demands high sensitivity at 3 mg/mmol cutoff & repeat-testing logic |
| Cystatin C | Confirmatory / GFR (G3a) | Refines eGFR in G3a gray zone; muscle-mass independent | Requires certified reference materials for global cross-platform harmonization |
Accelerate Your Renal Biomarker Assay Development with CamelBio
Whether you are developing high-throughput CKD screening tools or precision reflex staging panels, CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials, technical support, and expert consulting. We guide your assay development through every stage—from concept to clinic—ensuring exceptional lot-to-lot consistency, standardized performance, and seamless guideline compliance.